Please use this identifier to cite or link to this item:
Title: Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.
Austin Authors: Cebon, Jonathan S ;Knights, Ashley J;Ebert, Lisa;Jackson, Heather M;Chen, Weisan
Affiliation: Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg VIC 3084, Australia
Issue Date: 1-Jun-2010
Publication information: Expert Review of Vaccines; 9(6): 617-29
Abstract: The rigorous evaluation of cancer vaccination requires evidence of benefit to patients with cancer or those at risk of relapse from the disease. Clinical trials are expensive and require considerable human and clinical resources in order to demonstrate this benefit. In the era of defined cancer antigens, it is possible to evaluate immunogenic targets, and assess the quality and magnitude of immune responses against these antigens following vaccination. Analyzing these surrogate end points complements clinical assessment and provides a depth of understanding to better inform trial evaluation and design. We have used the immunogenic cancer testis antigen NY-ESO-1 as a model antigen. This article summarizes our experience in monitoring immunity against NY-ESO-1.
Gov't Doc #: 20518717
DOI: 10.1586/erv.10.58
Type: Journal Article
Subjects: Antigens, Neoplasm.immunology
CD4-Positive T-Lymphocytes.immunology
CD8-Positive T-Lymphocytes.immunology
Cancer Vaccines.immunology
Membrane Proteins.immunology
Skin Tests
T-Lymphocytes, Regulatory.immunology
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.